Cancer clinical trials in the region Pays de la Loire

413 currently recruiting clinical trials
Region Pays de la Loire

Phase 3 CLL & Richter's syndrome #NCT07277231 #2025-524366-21-00
Required histologic types
CLL (Chronic Lymphocytic Leukemia)
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
4 recruiting sites
BeOne Medecines
Phase 3 Head and neck cancer #NCT06129864
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Radiochemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Surgery Radiotherapy
8 recruiting sites
AstraZeneca
Phase 3 Kidney cancer #NCT07011719 #2024-515023-11-00
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
9 recruiting sites
Arcus Biosciences
Phase 3 Lymphoma #NCT06091865 #2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
15 recruiting sites
Regeneron Pharmaceuticals
Phase 3 Lymphoma #NCT06091865 #2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
15 recruiting sites
Regeneron Pharmaceuticals
Phase 3 Colon cancer Rectal cancer #NCT06997497 #2024-517232-22-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06510374
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
10 recruiting sites
Ferring Pharmaceuticals
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05198960
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera Essential thrombocythemia Primary myelofibrosis
Required genetic anomalies
JAK2
19 recruiting sites
Hôpital Universitaire de Brest
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06479135
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Targeted therapy
14 recruiting sites
Kartos Therapeutics
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06093672 #2022-502276-23-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera
Required genetic anomalies
JAK2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Targeted therapy Cytoreductive therapy
9 recruiting sites
Italfarmaco